

Our Ref: 399/2022

October 2022

## Re: Your request made under the Freedom of Information Act 2000

I have a freedom of information query regarding the use of Biologic medicines in gastroenterology. Could you please answer the following two questions:

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- |                          |                            |
|--------------------------|----------------------------|
| 1. Adalimumab – Humira   | 18 (via Homecare Pathway)  |
| 2. Adalimumab Biosimilar | 180 (via Homecare Pathway) |
| 3. Filgotinib            | NONE via Homecare          |
| 4. Golimumab             | 4 (via Homecare Pathway)   |
| 5. Infliximab – Remicade | NONE via Homecare Pathway  |
| 6. Infliximab Biosimilar | 4 (via Homecare Pathway)   |
| 7. Ozanimod              | NONE via Homecare Pathway  |
| 8. Tofacitinib           | NONE via Homecare Pathway  |
| 9. Ustekinumab           | 68 (via Homecare Pathway)  |
| 10. Vedolizumab          | 16 (via Homecare Pathway)  |

Unable to comment on numbers of patients receiving the medication via the Day Units or Outpatients Pharmacy due to the Cost Centre codes used.

Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:

1. Adalimumab - Humira
2. Adalimumab Biosimilar
3. Filgotinib
4. Golimumab
5. Infliximab - Remicade
6. Infliximab Biosimilar
7. Ozanimod
8. Tofacitinib

Our Ref: 399/2022

October 2022

9. Ustekinumab
10. Vedolizumab

- **Our pharmacy system doesn't store diagnosis data, so we're unable to determine this against the prescribed treatment. To ascertain this data, the Trust would need to perform an audit of each individual patient record, which wouldn't be achievable within the s.12 timescale of the Freedom of Information Act 2000.**